NCT06795945已完成不适用
Evaluate the Safety of a Bovine Thymus Nuclear Extract
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- To assess the safety and tolerability of Thymus Nuclear Extract at 3 dose levels
研究概览
简要总结
The goal of this trial is to find out if Thymus Nuclear Extract is safe and well-tolerated in healthy men and women by testing three different dose levels and comparing the results to a placebo.
详细描述
This is a 12 to 25 week study (if study participants are willing to follow up on study results) where participants are randomly assigned to groups and neither they nor the researchers know who receives Thymus Nuclear Extract or a placebo. The trial focuses on evaluating the safety of the extract in healthy adults by monitoring for adverse events and conducting safety assessments throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female participants who are between 18 - 65 years of age (inclusive).
- •In good general health (i.e., no uncontrolled diseases or conditions) as deemed by the investigator and are able to consume the study product.
- •Have a body mass index (BMI) range of 18.5 - 29.9 kg/m2 (inclusive).
- •Agree to follow the restrictions on concomitant treatments as listed.
- •Agree to use acceptable contraceptive methods as listed.
- •Willing and able to agree to the requirements of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
- •Agree to the dosage instructions including the oral consumption of 8 tablets twice daily.
排除标准
- •Individuals who are lactating, pregnant or planning to become pregnant during the study, or demonstrates a positive pregnancy test at Visit
- •Have a known sensitivity, intolerability, or allergy (especially to bovine products) to any of the study products or their excipients.
- •Have Type I diabetes, uncontrolled Type II diabetes, uncontrolled high blood pressure (≥140 systolic or ≥90 diastolic mmHg), or uncontrolled thyroid disease ("uncontrolled" defined as being unmedicated, have an unstable use of medication within 3 months prior to screening, or have a stable use of medication for 3 months but still have uncontrolled conditions).
- •Have a chronic inflammatory condition (e.g., rheumatoid arthritis, lupus, or multiple-sclerosis).
- •Have a neurological disorder which may impact cognitive testing (e.g., traumatic brain injury, epilepsy, neurodegenerative diseases).
- •Have received an organ transplant or other forms of allografts or xenografts.
- •Participants with sleep disorders (e.g., insomnia, sleep apnea, restless legs syndrome, narcolepsy, or any other condition that significantly affects sleep quality and duration)
- •Have medical condition(s) known to interfere with absorption, distribution, metabolism, or excretion of the study product (e.g., Crohn's disease, short bowel, acute or chronic pancreatitis, or pancreatic insufficiency).
- •Have a history of heart/cardiovascular disease, renal disease (dialysis or renal failure), hepatic impairment/disease, immune disorders and/or immunocompromised (i.e., HIV/AIDS).
- •Have a history of cancer (except localized skin cancer without metastases or in situ cervical cancer), unless recovery occurred more than 5 years before the screening visit.
- •Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.).
- •Reports a clinically significant illness during the 28 days before the first dose of study product.
- •Major surgery in 3 months prior to screening or planned major surgery during the study.
- •Have a history of alcohol or substance abuse in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program) or use that in the opinion of the investigator may be of a concern for the study.
- •Current enrollment or past participation in another study with any product(s) with at least one active ingredient within 28 days before first dose of study product or longer, if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.
- •Any other medical condition/situation or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to participate in the study or its measures or pose a significant risk to the participant.
研究组 & 干预措施
TPG1
Active Comparator
Thymus Nuclear Extract Dose 1
干预措施: TPG1 (Dietary Supplement)
TPG2
Active Comparator
Thymus Nuclear Extract Dose 2
干预措施: TPG2 (Dietary Supplement)
TPG3
Active Comparator
Thymus Nuclear Extract Dose 3
干预措施: TPG3 (Dietary Supplement)
PL
Placebo Comparator
Placebo
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
To assess the safety and tolerability of Thymus Nuclear Extract at 3 dose levels
时间窗: 12 weeks
Heart rate (bpm)
To assess the safety and tolerability of Thymus Nuclear Extract at 3 dose levels.
时间窗: 12 weeks
Whole blood hemoglobin (g/dL)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Serum-Free Thymus Transplantation in DiGeorge AnomalyDiGeorge AnomalyNCT00849888Sumitomo Pharma Switzerland GmbH2
撤回
3 期
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)Cardiac Allograft VasculopathyNCT01157949Cedars-Sinai Medical Center
已完成
1 期
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in AdultsSmallpoxNCT00079820Sanofi Pasteur, a Sanofi Company110
Unknown
不适用
Antithymocyte Globulin as a Second Line Therapy in Graves OrbitopathyGraves OrbitopathyNCT05199103Medical University of Silesia20
Unknown
不适用
A Study to Evaluate the Effect and Tolerance of Musclin™ (Thymol) in Healthy SubjectsHealthy VolunteersNCT03767504Innovus Pharmaceuticals, Inc.20